HeyJaredManuela Callari
- Indexed articles, last 90 days
- 16
- Latest publication
- Sep 30, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 8, 2026
Latest articles
Nondrug Strategies Fortify Host Resilience in Lung Infection (opens the original)
Read excerpt
BARCELONA, Spain — Lower respiratory tract infections cause millions of deaths worldwide each year. While modern medicine remains focused on prescribing antimicrobial drugs to eliminate pathogens, experts argue that infection prevention through nonpharmacologic interventions such as nutrition and microbiome, pulmonary rehabilitation, and environmental exposure can reduce reliance on antibiotics — necessary to counter worsening antimicrobial resistance. “Respiratory infection should not begin wit
Tozorakimab Reduces COPD Exacerbations (opens the original)
Read excerpt
BARCELONA, Spain — Add-on treatment with tozorakimab, a first-in-class monoclonal antibody targeting interleukin-33 (IL-33), significantly reduces the yearly rate of moderate and severe COPD exacerbations in patients receiving stable standard-of-care inhaled maintenance therapy. Results from the replicate phase 3 OBERON and TITANIA trials, presented at the European Respiratory Society (ERS) 2026 International Congress and simultaneously published in The New England Journal of Medicine, demonstra
Stem Cell Engraftment May Open New Opportunities for CF, PCD (opens the original)
Read excerpt
BARCELONA, Spain — For the millions of people living with genetic lung conditions, recent therapeutic advancements have improved clinical management. But for patients with cystic fibrosis (CF), who carry rare mutations, and those with primary ciliary dyskinesia (PCD), no targeted options are available. Meanwhile, next-generation delivery strategies such as viral vectors and lipid nanoparticle-mRNA platforms continue to fail against the formidable physical defensive barrier of the human airway ep
Rethinking Viral COPD by Targeting Triggers, Inflammation (opens the original)
Read excerpt
BARCELONA, Spain — Managing an acute viral flare-up of chronic obstructive pulmonary disease (COPD) involves prescribing a course of oral corticosteroids, broad-spectrum antibiotics, and hoping the patient’s lungs recover. But experts at the European Respiratory Society (ERS) 2026 International Congress argued that this nonspecific, syndromic rescue model is ineffective. Respiratory viruses trigger roughly half of all COPD exacerbations, and even a single moderate event permanently alters a pati
Experts Debate Combination Therapy for Pulmonary Fibrosis (opens the original)
Read excerpt
BARCELONA, Spain — For more than a decade, the standard clinical management of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis relied almost exclusively on two antifibrotic medications: pirfenidone and nintedanib. These antifibrotic therapies slow disease progression, but don’t stop it. Now, with a wave of novel therapeutic agents targeting distinct biological pathways entering phase 3 clinical trials, respiratory clinicians discuss whether to initiate combination antifibr
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.